These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 2303102

  • 1. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO).
    Johnson CS, Cook CA, Furmanski P.
    Exp Hematol; 1990 Feb; 18(2):109-13. PubMed ID: 2303102
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Modulation of erythropoiesis and myelopoiesis by exogenous erythropoietin in human long-term marrow cultures.
    Mayani H, Guilbert LJ, Janowska-Wieczorek A.
    Exp Hematol; 1990 Mar; 18(3):174-9. PubMed ID: 2303109
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment.
    Nijhof W, Goris H, Dontje B, Dresz J, Loeffler M.
    Exp Hematol; 1993 Apr; 21(4):496-501. PubMed ID: 8462658
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor exerts dose-dependent effects on erythropoiesis and myelopoiesis in vivo.
    Ulich TR, del Castillo J, Yin S.
    Exp Hematol; 1990 May; 18(4):311-5. PubMed ID: 2323367
    [Abstract] [Full Text] [Related]

  • 8. Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy.
    de Haan G, Engel C, Dontje B, Loeffler M, Nijhof W.
    Cancer Res; 1995 Jan 15; 55(2):324-9. PubMed ID: 7529132
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor.
    Dybedal I, Larsen S, Jacobsen SE.
    J Immunol; 1995 May 15; 154(10):4950-5. PubMed ID: 7537295
    [Abstract] [Full Text] [Related]

  • 11. Possible role of tumor necrosis factor-alpha in erythropoietic suppression by endotoxin and granulocyte/macrophage colony-stimulating factor.
    Udupa KB, Sharma BG.
    Am J Hematol; 1996 Jul 15; 52(3):178-83. PubMed ID: 8756083
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
    Carozzi S, Nasini MG, Santoni O, Tirotta A, Sanna A.
    ASAIO J; 1997 Jul 15; 43(5):M535-8. PubMed ID: 9360100
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D, Strife A, Atzpodien J, Clarkson BD.
    Cancer Res; 1987 Sep 15; 47(18):4788-94. PubMed ID: 3040231
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
    Chen J, Jacobs-Helber SM, Barber DL, Sawyer ST.
    Exp Cell Res; 2004 Aug 01; 298(1):155-66. PubMed ID: 15242770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.